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In kidney disease, the progressive loss of renal capacity to
produce calcitriol, the vitamin D hormone, is a key
contributor to elevations in parathyroid hormone (PTH) and
mineral and skeletal disorders predisposing to renal and
cardiovascular damage, ectopic calcifications, and high
mortality rates. Thus, the safe correction of calcitriol
deficiency to suppress PTH has been the treatment of choice
for decades. However, recent epidemiological and
experimental data suggest that calcitriol replacement may
improve outcomes through renal and cardioprotective
actions unrelated to PTH suppression. Furthermore, a striking
incidence of vitamin D deficiency occurs in kidney disease
and associates more strongly than calcitriol deficiency with a
higher risk for kidney disease progression and death. Despite
the translational relevance of these findings, no prospective
trials are currently available in support of the efficacy of
vitamin D supplementation and/or calcitriol replacement to
safely halt/moderate renal disease progression. This review
updates the pathophysiology behind the vicious cycle by
which kidney injury impairs the maintenance of normal
vitamin D and calcitriol levels, which in turn impedes
vitamin D/calcitriol renoprotective actions, a requirement
for the design of prospective trials to improve current
recommendations for vitamin D interventions at all stages
of kidney disease.
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The integrity of the vitamin D endocrine system is essential
for human health. The critical role of vitamin D in disease
prevention extends beyond mineral homeostasis and
skeletal integrity.1 Vitamin D deficiency in otherwise healthy
individuals associates not only with the expected reductions
in intestinal calcium absorption causing elevations in
parathyroid hormone (PTH) and bone loss, but also with
increased risk of hypertension, cardiovascular disease, glucose
intolerance, certain infectious diseases, autoimmune dis-
orders as multiple sclerosis and rheumatoid arthritis, cancer1
and, more significantly for this review, with albuminuria, a
hallmark of an abnormal kidney function.2
THE KIDNEY/VITAMIN D ENDOCRINE SYSTEM AXIS:
A TRANSLATIONAL OVERVIEW
The regulation of the expression of the numerous
vitamin D-responsive genes involved in the health benefits
of a normal vitamin D status requires the activation of
the vitamin D receptor (VDR) by 1,25-dihydroxyvitamin D
(calcitriol, the vitamin D hormone and, therefore, the most
active vitamin D metabolite; reviewed in Holick1 and Dusso
et al.3 and summarized in Figure 1). Normal renal function is
essential to maintain the endocrine actions of the calcitriol/
VDR complex because the kidney is the main site for the
conversion of 25-hydroxyvitamin D (25(OH)D) to circulat-
ing calcitriol. Normal serum calcitriol, in turn, contributes to
maintain VDR content in target tissues because calcitriol
binding to the VDR protects the VDR from proteosomal
degradation.4 In chronic kidney disease (CKD), the progres-
sive loss of renal capacity to produce calcitriol results in low
serum calcitriol, decreased tissue VDR content, and conse-
quently, in markedly impaired calcitriol/VDR actions
important for health, such as the suppression of the PTH
gene. Elevated serum PTH causes skeletal abnormalities and
disturbances in calcium and phosphate homeostasis predis-
posing to renal and cardiovascular damage, ectopic calcifica-
tions, and high mortality rates.5 Thus, for almost 30 years,
the therapy of choice to halt/moderate the elevations in
serum PTH has been the safe correction of calcitriol
deficiency with either calcitriol or its less calcemic analogs
(now referred to as ‘active’ vitamin D therapy because these
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vitamin D metabolites are the most potent VDR activators).
However, there is epidemiological and preclinical evidence
that reductions in serum PTH reflect only one aspect of
the efficacy of VDR activation with ‘active’ vitamin D therapy
to improve clinical outcomes. Specifically, two large observa-
tional studies in the United States6 and South America7
showed that hemodialysis patients receiving either intrave-
nous6 or oral7 ‘active’ vitamin D therapy live longer
compared with those not receiving any active vitamin D
metabolites. However, the survival benefits could not be
totally accounted for by PTH suppression.6 In addition, the
greatest survival benefits of oral active vitamin D therapy
were seen for the lower doses,7 which suggests that the high
doses of active vitamin D metabolites required to compensate
for the low parathyroid VDR in advanced kidney disease may
have adverse effects on VDR prosurvival actions unrelated to
PTH suppression.
The comprehensive search for the PTH-independent
prosurvival actions of active vitamin D therapy identified
three critical renal and cardioprotective properties in
experimental models of kidney disease: (1) the inhibition of
the renin-angiotensin II (RAS) system, (2) the attenuation of
systemic and renal interstitial inflammation, and (3) the
reduction of proteinuria (reviewed in Andress8). Intriguingly,
a recent assessment of the efficacy of vitamin D interventions
in predialysis and dialysis patients by the Cochrane Renal
Group, using current epidemiological standards, concluded
that there are no well-designed, adequately powered studies
to support the benefits of ‘active’ vitamin D interventions on
clinical outcomes.9,10 The disappointing discrepancy in the
evidence of the efficacy of ‘active’ vitamin D therapy to
improve outcomes between preclinical and clinical studies led
to the identification of the prevalent role of vitamin D
deficiency over that of calcitriol deficiency in renal disease
progression and death. Indeed, there is a striking 80%
incidence of vitamin D deficiency in CKD,11 an intriguing
finding because the main site for the conversion of vitamin D
to 25(OH)D is the liver, not the kidney.3 Vitamin D
deficiency is a recognized risk factor for all-cause mortality
in the general population.12 In fact, in spite of normal kidney
function and normal serum calcitriol, individuals with serum
25(OH)D in the lowest quartile (o17.8 ng/ml) elicit 26%
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Figure 1 |Vitamin D bioactivation and actions. Classical and nonclassical vitamin D actions require vitamin D conversion to
25-hydroxyvitamin D (25(OH)D, open circle), and its bioactivation to its hormonal form 1,25-dihydroxyvitamin D (calcitriol, diamond) by
renal and extrarenal 1-hydroxylase and calcitriol binding to and activation of its receptor, the vitamin D receptor (VDR). Calcitriol-activated
VDR binds its partner the retinoic X receptor (RXR, heterodimerization) and vitamin D-responsive elements (VDRE) in the promoter of
VDR-responsive genes (DNA binding), and recruits basal transcription factors (B) and co-activator and co-repressor molecules (CoReg) to
induce or repress the transcription of vitamin D-responsive genes by RNA polymerase II (transcriptional regulation). The net balance
between cellular uptake of calcitriol and/or 25(OH)D, the rate of 25(OH)D conversion to calcitriol versus the activity of 24-hydroxylase
(cyp24), responsible for the inactivation of 25(OH)D and calcitriol (crossed blue circle and purple diamond), determines the degree of VDR
activation by intracellular calcitriol. Most of these steps are impaired in kidney disease. Ca, calcium; P, phosphate; RAAS, renin-angiotensin-
aldosterone system.
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higher mortality rates.12 (Note that serum 25(OH)D rather
than direct measurements of serum vitamin D levels are used
to evaluate vitamin D status only because serum 25(OH)D is
directly proportional to serum vitamin D levels and easier
to measure.) Furthermore, low serum 25(OH)D levels are
better predictors than low serum calcitriol of the risk for
disease progression to end-stage renal disease and death
in predialysis patients,13 and for early mortality in hemo-
dialysis patients.14 Although a strong association between
vitamin D deficiency and a higher risk of death is by no
means a proof of causality, the safe correction of vitamin D
deficiency is becoming a high priority among nephrologists,
and obviously, it cannot be corrected with active vitamin D
therapy.
One recognized mechanism linking vitamin D deficiency
with a higher risk for all-cause mortality in the presence of
normal serum calcitriol is a defective local conversion of
25(OH)D to calcitriol by ‘nonrenal’ cells15 for the autocrine/
paracrine activation of the VDR that triggers cell-specific
prosurvival actions (see Figure 1). In CKD patients, however,
vitamin D supplementation to raise the low serum 25(OH)D
to normal levels may not suffice to correct the defec-
tive autocrine/paracrine VDR activation because CKD also
impairs the uptake of 25(OH)D by nonrenal cells expressing
1-hydroxylase.16
In summary, CKD induces a vicious cycle by which renal
damage decreases serum 25(OH)D and calcitriol levels,
calcitriol/VDR endocrine actions, and/or autocrine/paracrine
actions that maintain not only skeletal integrity, but also
cardiovascular and renal health. To help improve current
recommendations for vitamin D interventions to halt the
onset and/or moderate the progression of this vicious cycle
for renal disease progression and death, this review presents:
(1) the pathophysiology behind the cell-specific abnormal-
ities induced by CKD on 25(OH)D and calcitriol metabolism
and on VDR activation causing skeletal, cardiovascular, and
renal damage; (2) the kinetics of vitamin D conversion to
25(OH)D that can help improve current recommendations
to correct vitamin D deficiency; and (3) potential serum
markers of the efficacy of vitamin D interventions to
attenuate renal and cardiovascular damage in a PTH-
independent manner.
RENAL REGULATION OF THE VITAMIN D ENDOCRINE SYSTEM
Vitamin D regulation of the expression of genes involved in
the skeletal, renal, and cardiovascular protection requires the
activation of the VDR through the endocrine/paracrine and
autocrine pathways shown in Figure 1. In cells lacking
cyp27b1 (1-hydroxylase), the enzyme that converts 25(OH)D
to calcitriol, the degree of VDR activation by ‘active’ vitamin
D therapy depends upon the intracellular calcitriol (analog)
content, which in turn is the result of a cell-specific net
balance between the uptake of calcitriol (analog) from the
circulation (endocrine), or of the calcitriol produced in the
nearby environment (paracrine), versus the rate of intracel-
lular calcitriol (analog) degradation. In renal and nonrenal
cells expressing 1-hydroxylase, there is also an autocrine
pathway for VDR activation by the calcitriol synthesized
intracellularly, which in turn depends upon the net balance
between the cell-specific rates of 25(OH)D uptake from the
circulation and that of 25(OH)D conversion to calcitriol
versus the rates of intracellular degradation of 25(OH)D and
calcitriol.
Importantly, 25(OH)D is a VDR activator also in cells that
do not express 1-hydroxylase because 25(OH)D can directly
bind and activate the VDR. Although 25(OH)D affinity for
the VDR is 100–200 times lower than that of calcitriol, it
circulates at concentrations in the order of ng/ml, a
thousand-fold higher than serum calcitriol levels (in the
order of pg/ml).3 In addition, 25(OH)D induces rapid
(within minutes) actions that are called ‘nongenomic’
because they do not involve a ‘direct’ regulation of the
expression of vitamin D-responsive genes. Nongenomic
actions of both 25(OH)D and calcitriol rapidly modulate
intestinal calcium transport, intracellular calcium levels, and/
or the phosphorylation, subcellular localization, and activity
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Figure 2 |Central role of renal calcitriol production in mineral
and skeletal homeostasis in health. Renal calcitriol (1,25D, black
lanes) production tightly controls the complex hormonal
feedback loops between parathyroid hormone (PTH; light gray
lanes) and fibroblast growth factor 23 (FGF23; dark gray lanes), as
well as calcium (Ca; black arrows) and phosphate (P; gray arrows)
fluxes between the intestine, bone, and the kidney that ensure
normal mineral homeostasis and skeletal integrity, while
preventing the excess of both ions predisposing to ectopic
calcifications. Kidney disease severely impairs the calcitriol/FGF23/
PTH loops (see text for details), as well as the renal uptake of 25-
hydroxyvitamin D bound to vitamin D-binding protein (DBP) from
the glomerular filtrate to maintain renal calcitriol synthesis.
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of proteins that can regulate VDR control of gene expression.
Interestingly, the VDR molecule has two functionally
distinct pockets for ligands that trigger either genomic or
nongenomic VDR actions.17 Therefore, 25(OH)D binding to
the nongenomic pocket of the cell membrane-associated
VDR can trigger rapid actions that enhance the genomic
actions of calcitriol or its analogs bound to the genomic VDR
pocket, as reviewed in Dusso et al.3
This section presents the pathophysiology behind the
impaired VDR activation caused by the distinct systemic and/
or cell-specific abnormalities in 25(OH)D uptake, calcitriol
synthesis, and 25(OH)D and calcitriol catabolism induced by
CKD and/or therapeutic interventions in CKD patients.
Tight regulation of renal calcitriol production in health
The kidney is essential for the maintenance of normal calcitriol
and 25(OH)D levels. In individuals with normal kidney
function, renal calcitriol synthesis and catabolism are tightly
regulated to coordinately integrate not only the well-character-
ized calcium (Ca)/calcitriol/PTH axis, but also the phosphate
(P)/calcitriol/fibroblast growth factor 23 (FGF23) loop that
maintain a healthy skeleton, while preventing an excess of Ca
and P ions that could lead to overmineralization of bone or
ectopic calcification (summarized in Figure 2, and reviewed in
Dusso et al.3 and Barthel et al.18). Briefly, a decrease in serum Ca
is sensed by the parathyroid glands that, to restore Ca balance,
rapidly enhance the secretion and/or synthesis of PTH.
Elevations in serum PTH induce Ca resorption from bone
and stimulate renal 1-hydroxylase expression and activity to
increase calcitriol synthesis and calcitriol-induced intestinal
Ca absorption. Upon Ca normalization, both Ca and calcitriol
close the loop by suppressing PTH synthesis and renal
1-hydroxylase expression and activity. Neither the mechanisms
for PTH-mediated induction of renal 1-hydroxylase nor the role
of the calcium-sensing receptor on Ca regulation of renal
1-hydroxylase are fully understood.3
Calcitriol also elevates serum P levels by promoting
intestinal absorption, renal reabsorption, and bone resorp-
tion. However, both high P and calcitriol induce FGF23
synthesis in bone,19 which in turn closes the calcitriol/P loop
not only by suppressing renal calcitriol synthesis through
direct inhibition of 1-hydroxylase expression, but also
by lowering serum P through the inhibition of renal P
reabsorption.20 Klotho, a b-glucuronidase initially implicated
in aging, is a key but incompletely characterized player in the
calcitriol/FGF23 loop. Klotho is essential for FGF receptor 1
activation by FGF23,21 and also a potent direct inhibitor of
renal 1-hydroxylase.21 In fact, the klotho-null mouse has the
same phenotype of high serum P and calcitriol as the FGF23-
null mouse in spite of high serum FGF23 levels.22 Klotho is
expressed at low levels in both the apical and basolateral
membranes of renal proximal tubule cells,23 and also exists in
a soluble form. The phosphaturic effects that follow
intravenous administration of klotho support the endocrine
actions of soluble klotho;24 however, its contributions to
suppress renal 1-hydroxylase are unknown.
The regulation of calcitriol catabolism by calcitriol, PTH,
and FGF23 also has a key role in the maintenance of normal
serum calcitriol for the Ca/calcitriol/PTH and P/calcitriol/
FGF23 loops. Indeed, in normal individuals, calcitriol induc-
tion of its own degradation prevails over calcitriol suppres-
sion of 1-hydroxylase to maintain normal serum calcitriol, as
calcitriol metabolic clearance rates increase only upon
increases in production rates.25
Vitamin D 24-hydroxylase (24-hydroxylase), an enzyme
constitutively expressed in the kidney, and induced by
calcitriol in virtually all vitamin D target cells,3 catalyzes
the biological inactivation of 25(OH)D, calcitriol, and its
analogs. The induction of 24-hydroxylase by active vitamin D
metabolites provides a fine tuning of their intracellular levels,
thereby preventing excessive local responses to calcitriol
(analog), as demonstrated by high serum calcitriol and signs
of vitamin D toxicity in the 24-hydroxylase-null mice, which
is unable to degrade endogenous calcitriol.26 The latter raises
concerns on the safety of interventions with specific
inhibitors of 24-hydroxylase, under development to counter-
act the resistance to calcitriol (analog) therapy caused by low
VDR levels in advanced kidney disease.
Serum levels of P, FGF23, and PTH regulate 24-hydroxy-
lase expression and activity in a reciprocal manner to their
control of 1-hydroxylase; that is, increased by high P27,28 and
FGF23,29 and reduced by PTH.30 Thus, the induction of
FGF23 by active vitamin D therapy31 could help moderate
the toxicity of an excess of active vitamin D metabolites by
suppressing renal 1-hydroxylase and by inducing 24-hydro-
xylase for their degradation.
Critical role of renal 25(OH)D uptake in calcitriol synthesis
and in the maintenance of serum 25(OH)D
Because of its lipophylic nature, 25(OH)D circulates in the
blood bound to its carrier, the vitamin D-binding protein
(DBP).3 Figure 3 shows that the plasma 25(OH)D bound to
DBP is filtered through the glomerulus and is internalized
into renal proximal tubular cells by megalin for its activation
to calcitriol. Megalin is an endocytic receptor also responsible
for the renal tubular reabsorption of albumin and other small
molecular weight proteins.32 Importantly, megalin-mediated
endocytosis of the 25(OH)D/DBP complex also ensures
the recycling of 25(OH)D to the circulation to maintain
the normal serum 25(OH)D levels required for extra-
renal calcitriol synthesis and autocrine VDR activation, as
demonstrated by the severe vitamin D deficiency of the
megalin-null mice in spite of normal glomerular filtration
rates.32
Abnormalities in calcitriol synthesis and 25(OH)D and
calcitriol catabolism in CKD
Progressive reductions in the ability of the kidney to maintain
serum 25(OH)D levels in the course of CKD aggravate
the degree of calcitriol deficiency caused by decreases in the
expression and/or activity of renal 1-hydroxylase. Indeed, the
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enhancement of serum 25(OH)D levels with 25(OH)D
supplementation attenuates the reductions in serum calcitriol
caused by decreases in remnant renal 1-hydroxylase and/or
the inhibition of renal 1-hydroxylase expression and activity
caused by a blunted response to high serum PTH,33,34
metabolic acidosis, and increases in serum levels of uremic
toxins,35 and high serum FGF23.36 The blunted response to
high PTH has been attributed to either uncoupling of the
PTH receptor/protein kinase A axis33 and also to the
inhibition of 1-hydroxylase activity by N-terminally trun-
cated PTH fragments or C-terminal PTH fragments.34 The
mechanism for FGF23 inhibition of renal 1-hydroxylase36 is
less clear because proximal tubular cells are unable to
respond to the high serum FGF23 with the expected
inhibition of P reabsorption that causes hypophosphatemia
in individuals with normal kidney function. It is possible
that increases in the release of soluble klotho from its
membrane-bound precursor by renal ADAM17 (also called
TACE (tumor necrosis-a-converting enzyme)), an enzyme
whose expression in the kidney is induced in mouse and
human CKD,37–39 could contribute to FGF23 suppression of
renal 1-hydroxylase. At early stages of kidney dysfunction,
TACE-mediated increases in the release of soluble klotho
could contribute to the suppression of renal 1-hydroxylase
that precedes elevations in serum P or FGF23. Also, in
advanced kidney disease, high serum PTH could aggravate
the release of soluble klotho induced by renal damage,
through a protein kinase C-mediated induction of distal
tubule TACE, as demonstrated for high PTH/protein kinase
C-mediated induction of TACE in osteoblast precursors.40
The importance of correcting vitamin D deficiency to
attenuate the reductions in serum calcitriol was conclusively
demonstrated in hemodialysis patients with a glomerular
filtration rate (GFR) o25ml/min and, therefore, with very
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Figure 3 |Defective renal 25(OH)D uptake impairs substrate availability to renal 1-hydroxylase in CKD. (a) Circulating 25(OH)D
(25D) bound to its carrier vitamin D-binding protein (DBP) is filtered by the kidney and internalized into proximal tubular cells via
megalin-mediated endocytosis. Upon its release from DBP, 25(OH)D is either delivered to 1-hydroxylase by intracellular vitamin D-binding
protein 3 (IDBP3) for its bioactivation to calcitriol (1,25D) or it re-enters the circulation. Calcitriol induces renal megalin expression, thereby
generating a cycle that ensures normal systemic 25(OH)D and calcitriol levels as well as the reabsorption of low-molecular-weight proteins
from the glomerular filtrate, including albumin. In chronic kidney disease (CKD), decreases in glomerular filtration rate (GFR) and low
megalin content contribute to impair 25(OH)D uptake and protein reabsorption. (b) The strong correlation between serum levels of
25(OH)D and calcitriol (1,25(OH)2D) in severely uremic patients (GFR o25ml/min), which is absent in normal individuals (dotted line),
demonstrates impaired 25(OH)D availability for its bioactivation to calcitriol by the remnant renal 1-hydroxylase in CKD. Only
supraphysiological concentrations of 25(OH)D normalize serum calcitriol levels. Adapted from reference Halloran et al.41
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limiting renal 1-hydroxylase, and with expected high serum
levels of FGF23.41 In these patients, the low serum calcitriol
could be normalized through 25(OH)D supplementation
that raised serum 25(OH)D to levels ofB100 ng/ml,41 in the
upper limit of the normal range.42 Furthermore, serum levels
of 25(OH)D and calcitrol strongly correlate (see Figure 3b),41
a correlation that was reproduced in dogs with mild and
moderate experimental kidney disease.43 The normalization
of serum calcitriol in response to 25(OH)D supplementation
in uremic dogs involves a twofold increase in calcitriol
production rates.43 Conclusive evidence will be presented
below, on the contributions of both renal and extrarenal
calcitriol production to the increases in serum calcitriol in
response to increases in serum 25(OH)D in human CKD.
The strong correlation between serum 25(OH)D and
calcitriol levels of CKD does not exist in individuals with
normal kidney function. Even in cases of vitamin D
intoxication, in which serum 25(OH)D levels raise up to
70-fold above normal, calcitriol levels are kept within the
narrow limits required for normal Ca homeostasis44 because
normal serum calcitriol levels are sufficient to induce 24-
hydroxylase to increase calcitriol catabolism. Importantly,
also in CKD, normal serum calcitriol appears to suffice to
induce its own degradation also in CKD because serum
calcitriol does not increase above normal levels in spite of
serum 25(OH)D concentrations 4100 ng/ml.41 This finding
questions the efficacy of exclusive 25(OH)D supplementation
to sustain calcitriol/VDR endocrine actions in advanced CKD
because normal calcitriol is insufficient to compensate for the
low tissue VDR content.
Impaired renal uptake of 25(OH)D in CKD
In the course of CKD, progressive decreases in GFRs and also
in renal megalin content45 contribute to impair the uptake of
25(OH)D by proximal tubular cells for its activation to
calcitriol by the remnant renal 1-hydroxylase and for
25(OH)D recycling to the circulation. The decreases in
GFR reduce the amount of 25(OH)D bound to DBP filtered
that is available for renal uptake, which can partially account
for the strong association between serum 25(OH)D and
calcitriol. Indeed, the administration of ergocalciferol
(vitamin D2) or cholecalciferol (vitamin D3) that effectively
elevates serum 25(OH)D levels will also enhance the
proportion of DBP carrying 25(OH)D in the blood and,
consequently, the amount of 25(OH)D filtered in spite of an
unchanged GFR.
Renal megalin content decreases rapidly upon the
induction of renal damage in the rat model of kidney
disease.45 Thus, megalin content in proximal tubular cells of a
failing kidney determine the 25(OH)D available for its
conversion to calcitriol by the remnant 1-hydroxylase
regardless of GFR and serum 25(OH)D levels. Interestingly,
renal megalin is induced by the calcitriol/VDR complex.46
Therefore, vitamin D deficiency could result in a defective
autocrine VDR activation in proximal tubular cells that
compromises the maintenance of renal megalin content,
thereby generating a vicious cycle for further impairments in
25(OH)D uptake, calcitriol production, and 25(OH)D
recycling to the circulation to maintain serum 25(OH)D
levels and autocrine VDR activation. Neither the contribu-
tions of vitamin D deficiency to reduce renal megalin content
nor the contributions of other factors that downregulate
megalin expression in CKD are known. However, reduced
renal megalin and proteinuria can contribute to the
difficulties of exclusive vitamin D supplementation to raise
serum 25(OH)D 435 ng/ml even at early stages of human
CKD (reviewed in Al-Badr et al.11). Al-Aly et al.47 showed
that onlyB50% of kidney disease patients with stages 3 and
4 successfully incremented the levels of 25(OH)D in response
to the standard vitamin D supplementation regimens.47 Also,
whereas a single bolus dose of cholecalciferol of 100,000 IU
effectively increases 25(OH)D levels 430 ng/ml in 93% of
healthy individuals,48 it should be provided once every 2
weeks to achieve similar levels in kidney transplant
recipients.49 Furthermore, this high dose fails to maintain
serum 25(OH)D when its administration regimen changes to
once every 2 months.49
The mild attenuation of proteinuria by early interventions
with calcitriol analogs50,51 suggests that the combination of
vitamin D supplementation and active vitamin D metabolites
may facilitate achieving the recommended serum 25(OH)D
threshold. However, the safety and the efficacy of such
combination need to be tested in preclinical studies and in
adequately powered prospective clinical trials. Indeed, at
early stages of CKD, it is important to avoid elevations in
25(OH)D above a threshold that could induce toxicity at
nonhypercalcemic doses of calcitriol or its analogs, as
demonstrated in a subgroup of normal women with normal
kidney function.12 Furthermore, in advanced CKD, the
induction of 24-hydroxylase expression and, consequently,
of 25(OH)D and calcitriol degradation in response to therapy
with active vitamin D metabolites may aggravate vitamin D
deficiency and its adverse effects on outcomes, or limit the
efficacy of vitamin D supplementation to correct the low
serum 25(OH)D.
Abnormal 25(OH)D and calcitriol catabolism in CKD
The impact of kidney disease on calcitriol degradation has
been controversial, as clinical and preclinical studies have
reported it to be reduced to compensate for the defective
synthesis,52,53 unchanged,43 and also increased, the latter
causing reduced intestinal calcium absorption in CKD
patients.54 Although a defective induction of 24-hydroxylase
was expected from the combination of low serum calcitriol,
reduced tissue VDR content, and high PTH, 24-hydroxylase
can be induced by metabolic acidosis55 and by increases in
FGF23,29 both common occurrences in advanced CKD. In
addition, the high dosage of active vitamin D compounds
required to suppress PTH in advanced CKD can induce
24-hydroxylase and, consequently, enhance the degradation
of 25(OH)D, endogenous calcitriol, and of the administered
active vitamin D metabolites. In fact, in 5/6 nephrectomized
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rats, the administration of the calcitriol analogs 22-oxacalci-
triol or paricalcitol, at doses effective in suppressing PTH,
reduces serum calcitriol to very low levels.56,57 Also, enhanced
expression of the pregnane X receptor, an important xeno-
biotic and drug-detoxifying receptor, and a potent inducer of
24-hydroxylase, could contribute to aggravate calcitriol
deficiency in CKD in a calcitriol (analog)-independent
manner.58
The 24-hydroxylase also inactivates 25(OH)D. However,
24-hydroxylase has a higher affinity for calcitriol than for
25(OH)D,3 which could cause a rapid and marked reduction
in serum calcitriol levels, as observed upon the administra-
tion of 22-oxacalcitriol or paricalcitol to uremic rats,56,57
before there are marked changes in serum 25(OH)D.
Therefore, in patients treated with calcitriol analogs, a
preferential degradation of serum calcitriol over 25(OH)D
by analog-induced 24-hydroxylase invalidates any compar-
ison of the relative accuracy of serum levels of 25(OH)D or
calcitriol to predict outcomes. The induction of 24-hydro-
xylase also compromises net calcitriol production by
nonrenal 1-hydroxylases, as demonstrated in bilaterally
nephrectomized patients undergoing hemodialysis.59 The
tissue/cell specificity for the induction of 24-hydroxylase by
high serum FGF23 could limit the efficacy of calcitriol or
analog therapy for endocrine VDR activation and that of
vitamin D supplementation for autocrine VDR activation
in a cell/tissue-specific manner.
Abnormalities in extrarenal calcitriol production in CKD
The impact of kidney disease on 25(OH)D uptake and
calcitriol synthesis by ‘nonrenal’ cells bearing 1-hydroxylase
was examined in peripheral blood monocytes from normal
individuals and hemodialysis patients because monocyte–-
macrophage 1-hydroxylase is identical to the renal enzyme,
though more readily accessible. Surprisingly, a higher rather
than a reduced expression of 1-hydroxylase was found in
monocytes derived from peripheral blood mononuclear cells
from hemodialysis patients compared with that in monocytes
from normal individuals.60 This suggests a role for the
1-hydroxylase of monocytes in compensating for the
defective calcitriol production by the proximal tubule
cells of a damaged kidney. The cause of the enhanced
1-hydroxylase expression in monocytes from hemodialysis
patients is unknown, as monocytes lack PTH receptors and
monocyte 1-hydroxylase does not respond to changes in
serum Ca and P levels as the renal enzyme does.60 The high
monocyte 1-hydroxylase content could result from the
inflammatory state of end-stage renal disease, as inflamma-
tory cytokines enhance monocyte 1-hydroxylase activity.61,62
However, in CKD, the enhanced 1-hydroxylase content in
monocytes appears to reflect a defective feedback inhibition
of the expression of the enzyme by the low serum calcitriol.
In fact, the Vmax of monocyte 1-hydroxylase, a direct
measurement of enzyme content in a cell, correlates inversely
with serum calcitriol, and is exquisitely sensitive to down-
regulation by physiological levels of serum calcitriol
(see Figure 4c).16 The tight suppression of monocyte
1-hydroxylase by physiological concentrations of serum
calcitriol in CKD does not occur in monocytes from patients
with sarcoidosis and other granulomatoses. To the contrary,
in these disorders, hypercalcemic episodes result precisely
from the inefficacy of the high serum calcitriol concentra-
tions to suppress calcitriol synthesis by the disease-activated
macrophages and to induce 24-hydroxylase.63
In relation to FGF23 regulation of nonrenal 1-hydro-
xylases, it is unclear whether the high levels of FGF23 of CKD
would compromise or enhance monocyte/macrophage calci-
triol production, as contrary to the inhibition of renal
1-hydroxylase, FGF23 enhances 1-hydroxylase mRNA levels
in cells from normal parathyroid glands.64 The decrease in
parathyroid klotho induced by CKD65 appears to limit FGF23
induction of parathyroid calcitriol production.
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Figure 4 |Calcitriol corrects the impaired 25(OH)D availability to nonrenal 1-hydroxylases in chronic kidney disease (CKD).
(a) The strong correlation between serum levels of 25(OH)D and calcitriol (1,25(OH)2D) in bilaterally nephrectomized patients
(anephrics) demonstrates impaired 25(OH)D availability for its bioactivation to calcitriol by nonrenal 1-hydroxylases. Only supraphysiological
concentrations of 25(OH)D normalize serum calcitriol levels. Adapted from reference Dusso et al.112 (b) 25(OH)D uptake (30min) at day 0
(left bar) and at day 15 (right bar) by peripheral blood monocytes from normal individuals (Normal) and hemodialysis patients (Uremic)
receiving either vehicle (Controls) or intravenous calcitriol (1,25(OH)2D) three times a week for 15 days. Modified from reference Gallieni
et al.16 (c) The Vmax of 1-hydroxylase in monocytes from hemodialysis patients, a marker of enzyme content, inversely correlates with serum
calcitriol levels, thus demonstrating a tight feedback inhibition of monocyte 1-hydroxylase expression by physiological levels of calcitriol.
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The distinct regulation of renal and parathyroid
1-hydroxylase by FGF23 and that of monocyte/macrophage
1-hydroxylase by CKD or inflammatory disorders provide
clear examples of the complexity behind the design of
effective vitamin D interventions that simultaneously
improve endocrine and autocrine/paracrine VDR actions
in the most relevant target cells. The relative contribution
of monocyte/macrophages and other cell types expressing
1-hydroxylase, for example, parathyroid cells and/or osteoblasts,
to serum calcitriol in CKD patients cannot be directly measured.
However, there is conclusive clinical evidence that the low serum
25(OH)D of CKD limits extrarenal calcitriol synthesis.
Impaired substrate availability to nonrenal 1-hydroxylases
in CKD
In anephric patients, the almost undetectable serum calcitriol
levels can be normalized through 25(OH)D supplementation
that increases serum 25(OH)D levels above the upper normal
limit of 100–200ng/ml.42,66 Furthermore, a strong correlation
exists between serum calcitriol concentrations and the levels of
its precursor 25(OH)D (see Figure 4). Importantly, serum
calcitriol does not raise above normal levels in spite of increases
in 25(OH)D concentrations up to 300ng/ml.59 These findings
support a local rather than an endocrine role for calcitriol
production by monocytes and other nonrenal 1-hydroxylases
in CKD. Furthermore, they also suggest that physiological
serum levels of calcitriol can suppress nonrenal calcitriol
synthesis, as shown for the decrease in the Vmax of monocyte
1-hydroxylase,16 and/or induce 24-hydroxylase and calcitriol
catabolism when the increases in production rate normalize
serum calcitriol, as already described in individuals with
normal renal function.25 Therefore, in advanced kidney disease,
the high concentrations of calcitriol or its analogs required to
suppress PTH could adversely impact calcitriol autocrine/
paracrine actions through feedback inhibition of 1-hydroxylase
expression and activity and also through the induction of
24-hydroxylase to degrade the already low serum 25(OH)D.
Both mechanisms can partially account for the loss of the
prosurvival benefits reported for the highest doses of oral
paricalcitol therapy.7 Indeed, in the rat model of renal
insufficiency, the fibrosis surrounding small cardiac arteries
correlates inversely with serum calcitriol, an effect unrelated to
changes in serum calcium, phosphate, or PTH levels.67
Intriguingly, paricalcitol treatment increased rather than
reduced perivascular fibrosis. Paricalcitol profibrotic actions
were unrelated to decreases in VDR levels and directly
associated with a marked reduction in serum calcitriol and
with a mild reduction in serum 25(OH)D compared with the
levels in untreated uremic rats. Importantly, paricalcitol-
induced reductions in serum calcitriol and 25(OH)D levels
could not be accounted for by increases in serum FGF23. Thus,
either paricalcitol exerts opposing effects to those of calcitriol in
the regulation of perivascular fibrosis, or paricalcitol inhibition
of net local calcitriol production was sufficient to reverse the
benefits of vitamin D autocrine/paracrine ‘suppression of
fibrogenic processes’ in the vasculature.
An additional important translational consideration to
that of defining the threshold of ‘active’ vitamin D
metabolites to avoid the loss of the benefits of auto-
crine VDR activation is that of determining the threshold
of 25(OH)D required to correct the defective extrarenal
calcitriol production for autocrine/paracrine calcitriol
actions.
Impaired uptake of 25(OH)D for its nonrenal bioactivation
to calcitriol
As indicated earlier, CKD not only induces vitamin D
deficiency but also impairs 25(OH)D uptake by nonrenal
cells expressing 1-hydroxylase,16 as demonstrated ex vivo by
the markedly lower uptake of 25(OH)D by monocytes from
hemodialysis patients compared with that in monocytes from
normal individuals (Figure 4b). Thus, normal serum
25(OH)D levels may be insufficient to sustain ‘autocrine/
paracrine’ calcitriol actions in CKD. Intriguingly, the
defective 25(OH)D uptake ex vivo by monocytes from
hemodialysis patients could be corrected through the
normalization of the low serum calcitriol by intravenous
calcitriol supplementation.16 Different from renal proximal
tubular cells, megalin expression in monocyte/macrophages
is not firmly established, and therefore, neither the mechan-
isms mediating the impaired 25-hydroxyvitamin D uptake
nor those involved in its correction by calcitriol treatment are
known. Megalin is a member of the low-density lipoprotein
receptor superfamily, and calcitriol modulates very-low-
density-lipoprotein receptor expression and function in the
human monocytic cell line HL60.68,69 A similar regulation of
low-density lipoprotein receptor levels by calcitriol in
monocyte/macrophages from hemodialysis patients could
partially contribute to the correction of their impaired
25(OH)D uptake.
A defective uptake of 25(OH)D also appears to occur
in parathyroid cells, which express 1-hydroxylase70,71 and
megalin,72 and suppress PTH in an autocrine/paracrine
manner through the local activation of 25(OH)D to
calcitriol.71 The pathophysiological relevance of an impaired
availability of 25(OH)D is suggested by the demonstration
that at early stages of CKD, ergocalciferol administration
reduces serum PTH exclusively in patients achieving serum
25-hydroxyvitamin D levels 430 ng/ml.47,73,74 The diffi-
culties in normalizing serum 25(OH)D in these patients
associated directly with the degree of proteinuria,11 which
supports the importance of normal kidney function to
maintain nonrenal calcitriol synthesis and autocrine/para-
crine VDR actions.
In summary, in the course of kidney disease, progressive
reductions in serum 25(OH)D levels and in renal and
extrarenal uptake of 25(OH)D determine the severity of the
defects in renal and extrarenal calcitriol synthesis causing low
serum calcitriol and impaired endocrine and autocrine/
paracrine VDR actions. Interestingly, whereas vitamin D
supplementation can correct the abnormal renal uptake of
25(OH)D for calcitriol production, calcitriol replacement can
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correct the abnormal uptake of 25(OH)D for nonrenal cells.
However, there are limitations to use ‘active’ vitamin D
interventions to improve the defective nonrenal calcitriol
production that impairs autocrine VDR activation, as normal
serum calcitriol is sufficient to inhibit the expression
of nonrenal 1-hydroxylases. Furthermore, the induction of
24-hydroxylase by the high doses of active vitamin D
metabolites required to counteract the reductions in VDR
and suppress PTH in advanced kidney disease can induce the
degradation of the low 25(OH)D levels, thereby aggravating
the degree of vitamin D deficiency and defective autocrine
VDR activation predisposing to higher risks for disease
progression and death. Also, the adverse effects of high serum
FGF23 could be partially accounted for by the induction of
24-hydroxylase to aggravate vitamin D deficiency and/or
impair the responses to calcitriol (analogs) and vitamin D
supplementation through the degradation of calcitriol
(analog) or 25(OH)D. The next section presents the current
understanding of the kinetics of vitamin D conversion to
25(OH)D and of the mechanisms for VDR activation by
25(OH)D that can help improve current recommendations
for the correction of vitamin D deficiency and VDR
activation in CKD.
Adequacy of current recommendations to correct vitamin D
deficiency
Current recommendations for vitamin D supplementation in
CKD often fail to correct vitamin D deficiency.11 According
to the KDOQI (Kidney Disease Outcomes Quality Initiative)
guidelines, in CKD stages 2 or 3, high serum PTH is an
indicator to evaluate vitamin D status and give weekly bolus
oral doses of 50,000 IU of either ergocalciferol (vitamin D2)
or cholecalciferol (D3) to reach serum 25(OH)D levels
430 ng/ml that effectively suppress PTH.11 However,
cholecalciferol and ergocalciferol are not equivalent. Upon
a bolus administration of 50,000–100,000 IU, the initial
increases in serum vitamin D and 25(OH)D levels for either
metabolite are identical only over the first 3 and 7 days,
respectively.75 Whereas in cholecalciferol-treated subjects
serum 25(OH)D3 levels continue to rise and peak by day
14, in ergocalciferol-treated individuals, serum 25(OH)D2
levels at day 14 are not different from baseline. The shorter
duration of the correction of vitamin D deficiency by
ergocalciferol due to the shorter half-life of 25(OH)D2
compared with that of 25(OH)D3
75 can be easily resolved
with daily oral doses of 2000 IU of either metabolite, which
results in identical increases in serum 25(OH)D from
baseline.76 Daily low doses have an additional advantage. In
normal individuals, almost 50% of the administered vitamin
D is rapidly converted to 25(OH)D at doses o2000 IU. In
contrast, much lower conversion rates occur with daily
vitamin D dosage 42000–4000 IU,77 suggesting that high
vitamin D doses are stored, likely in the body fat, and slowly
released to be converted to 25(OH)D.77 Although the impact
of CKD on vitamin D storage, metabolism, and the rates of
conversion to 25(OH)D is unknown, the correction of
vitamin D deficiency with daily dosage of either ergocalciferol
or cholecalciferol or weekly bolus doses of cholecalciferol,
but not ergocalciferol, should better ensure the maintenance
of serum 25(OH)D levels 430 ng/ml. Also, in view of the
slower conversion to 25(OH)D of bolus doses of vitamin D
in normal individuals, the relative efficacy of daily versus
weekly equivalent doses of cholecalciferol needs to be re-
assessed.
Direct supplementation with 25(OH)D is available in
Europe. Its benefit is the instant achievement of serum
25(OH)D 435 ng/ml in CKD. However, dosage and timing
should be markedly different from those for vitamin D
supplementation because 25(OH)D can directly bind and
activate the VDR and it stays longer in the blood because its
half-life is 15 to 18 days. Clearly, daily or weekly regimens
could result in increases in serum 25(OH)D concentrations
to toxic levels (4200 ng/ml42,66). 25(OH)D binds DBP with
an affinity up to 600 times stronger than that of calcitriol.78
Although only 5% of circulating DBP suffice to bind all
vitamin D metabolites combined, it was considered that the
cause of the toxicity in vitamin D intoxication was the
displacement of calcitriol from DBP to increase ‘free’
calcitriol levels to enter target cells, as total serum calcitriol
remains unchanged.79 Direct VDR activation by high serum
25(OH)D can also contribute to vitamin D toxicity. The
prolonged half-life of 25(OH)D in the circulation and
25(OH)D potential as a VDR activator and as an enhancer
of the genomic actions of the calcitriol (analog)/VDR
complex can partially account for the U-shaped curve when
plotting mortality rates against serum 25(OH)D levels in
individuals with normal kidney function and normal serum
calcitriol levels.12 In fact, the survival benefits associated with
the correction of vitamin D deficiency appear to start
reversing to mild increments in mortality rates for 25(OH)D
concentrations 450 ng/ml.12 Although the increases in
mortality rates reach statistical significance only in a
subgroup of normal women, this finding has important
therapeutic implications regarding the safety and the efficacy
of vitamin D supplementation to improve outcomes at all
stages of CKD. On one hand, it suggests that nutritional
vitamin D can induce toxicity even at not hypercalcemic
doses of calcitriol or its analogs. On the other hand, it also
suggests that vitamin D supplementation could allow a
reduction in the dosage with calcitriol or its analogs that is
required to compensate for the resistance to active vitamin D
therapy caused by reduced VDR content.
The section below presents the existing preclinical and
clinical evidence of the relative contribution of endocrine
versus paracrine/autocrine VDR activation to skeletal, renal,
and cardiovascular protection.
VITAMIN D REGULATION OF KIDNEY FUNCTION
For more than two decades, the interest of nephrologists on
the vitamin D endocrine system has been that of protecting
the kidney from further declines in renal function resulting
from the hypercalcemic and hyperphosphatemic effects of
Kidney International (2011) 79, 715–729 723
AS Dusso and M Tokumoto: Interactions between kidney and vitamin D endocrine system t rans la t iona l nephro logy
calcitriol replacement therapy to treat secondary hyperpar-
athyroidism. In fact, the first prospective randomized trials
with moderate doses of active vitamin D metabolites in
patients with mild to moderate CKD emphasized the benefits
of therapy with calcitriol or its less calcemic analogs in
reducing serum PTH levels and improving bone health, with
no adverse impact on renal function.80–82
In recent years, previous dogmas about calcitriol (analog)
upregulation of renal P reabsorption to aggravate P retention
and, with it, the severity of secondary hyperparathyroidism
and ectopic calcifications has been challenged. In addition to
increases in the filter load of P through the enhancement of
intestinal P reabsorption, calcitriol directly increases renal P
re-absorption by inducing the renal sodium–phosphate co-
transporter NaPi-IIc.18 This transporter has a minor role in
renal phosphate reabsorption in rodents, but mutations in
this gene cause the human P wasting disorder of hereditary
hyperphosphatemic rickets with hypercalciuria.83,84 However,
calcitriol also induces serum FGF23 and klotho, two
potent inducers of phosphaturia and suppressors of renal
1-hydroxylase.85 In addition, calcitriol induction of renal
megalin may contribute to the phosphaturic response of
proximal tubule cells to PTH and FGF23. Megalin is essential
for the maintenance of adequate steady-state expression of
the sodium/P co-transporter IIa (NaPi-IIa) and for the
capacity of proximal tubular cells to react to PTH-driven
inactivation of NaPi-IIa by endocytosis and intracellular
translocation.86 Kidney-specific inactivation of the megalin
gene results in markedly reduced phosphaturia because of
enhanced steady-state levels of NaPi-IIa in the brush border
membrane, and a defective retrieval and impaired degrada-
tion of NaPi-IIa in response to PTH.86 Correction of renal
megalin levels by early interventions with paricalcitol could
partially account for the efficacy of the analog in ameliorating
albuminuria at early stages of kidney disease50 and for
the low phosphatemic activity of the analog. In normal
individuals and in renal graft recipients, vitamin D deficiency
could result in a defective autocrine induction of renal
megalin content in proximal tubular cells, thereby predis-
posing to the development of low molecular weight
proteinuria and abnormalities in renal megalin/NaPi-IIa
handling of P. Indeed, the enhancement of vitamin D
supplementation to 100,000 IU every 2 weeks effectively
prevented elevations in serum PTH and the abnormalities in
mineral homeostasis that involve renal handling of Ca and P
and that compromise graft survival in kidney transplant
recipients.49
More significantly, in contrast to the valid fears on the
potential adverse renal effects of active vitamin D therapy,
emerging experimental data support an important renopro-
tective role for active vitamin D metabolites against renal
injury. As recently reviewed by Li and co-workers,87 studies
in experimental models of kidney disease have clearly
established that calcitriol analogs were effective in: (1) the
control of tubulointerstitial fibrosis in unilateral ureteral
obstruction, a well-established model of tubulointerstitial
fibrosis of the kidney; (2) the amelioration of glomerulo-
sclerosis in the anti-thy-1 model of antibody-induced
glomerulonephritis; (3) the attenuation of nuclear factor-
kB-driven inflammation and profibrotic pathways in diabetic
nephropathy; (4) the repression of the activation of the renin-
angiotensin-aldosterone system in the subtotal nephrectomy
rat model that recapitulates the renal insufficiency seen in
advanced stages of CKD. Indeed, in this rat model, the
vitamin D analog paricalcitol was shown to synergize with
RAS inhibition to reduce inflammatory renal lesions; and
(5) the reduction of glomeruloesclerosis, albuminuria, and
podocyte injury and also in enhancing the efficacy of renin-
angiotensin-aldosterone system inhibition in experimental
models of diabetes by blocking the compensatory increase of
renin expression. Indeed, in the VDR-null diabetic mouse, a
more robust activation of the local RAS in the kidney is the
cause of a more severe renal injury.
In human kidney disease, calcitriol administration was
shown to lower the rate of loss of renal function in a
retrospective study in renal transplant patients with chronic
allograft nephropathy.88 Also, a small trial in 24 patients
(22 CKD stage 3, and 2 CKD 2) using 1 and 2mg of oral
paricalcitol supports the antiproteinuric effects of the analog
demonstrated in CKD stages 3 and 4.50 Paricalcitol reduction
of albuminuria and systemic inflammation, measured by
serum levels of C reactive protein, was unrelated to the
control of blood pressure or serum PTH.51
The strong association between vitamin D deficiency and
albuminuria in the general population, and the demonstra-
tion that vitamin D deficiency is an accurate predictor of the
risk of development of end-stage renal disease and death,13
support the potential renoprotective benefits of autocrine/
paracrine VDR activation. Although neither report proves
that vitamin D deficiency causes renal disease progression or
death, the potential renoprotective benefits of its safe
correction need to be examined in prospective trials.
Vitamin D deficiency as a contributor to the development
and progression of renal lesions
In vitamin D-deficient individuals with normal renal
function, in spite of a normal GFR, the low serum
25(OH)D levels will markedly reduce the levels of
25(OH)D filtered and available for uptake by renal proximal
tubular cells, thereby compromising its activation to
calcitriol, and calcitriol/VDR induction of renal megalin for
urinary protein reabsorption.89 Indeed, the low molecular
weight proteinuria of Dent’s disease90 and Fanconi syn-
drome91 results from reduced megalin expression in renal
proximal tubular cells and/or abnormalities in the recycling
of cytosolic megalin to the brush border membrane. Urinary
protein is a recognized determinant of renal disease
progression and higher risk for cardiovascular complica-
tions.92 In fact, the cross-presentation of antigenic peptides
from tubular cell-processed albumin by proximal tubule-
associated dendritic cells reinforces tolerance in a normal
kidney, and an active immune response in the proteinuric
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kidneys.93 It is therefore possible that in vitamin D-deficient
states, impaired calcitriol autocrine/paracrine actions in
dendritic cells, in which calcitriol promotes the main-
tenance of a tolerogenic phenotype,94 contribute to aggravate
nonimmune-mediated proteinuric nephropathy. Once the
albumin-driven inflammatory response is initiated, vitamin
D deficiency will also limit calcitriol production by mono-
cyte/macrophages, which can contribute to impair calcitriol
autocrine/paracrine anti-inflammatory properties,95 thereby
aggravating macrophage infiltration, and lesions to the renal
parenchyma. This is not mere speculation, as vitamin D
deficiency is sufficient to disable macrophage antimycobac-
terial activity in the African-American population, thereby
enhancing the risk of tuberculosis.96 Mechanistically, low
serum 25(OH)D levels cause a defective activation of
25(OH)D to calcitriol by the 1-hydroxylase of the infected
macrophage, which in turn markedly impairs a key autocrine
calcitriol/VDR action: the induction of the gene that
codes for cathelicidin, a potent anti mycobacterial molecule.
Indeed, vitamin D supplementation is sufficient to restore
normal cathelicidin mRNA levels in monocytes.
In renal transplant recipients, an early correction of serum
25(OH)D levels, either before or at transplantation, could
help maintain renal megalin levels, 25(OH)D uptake, and
protein reabsorption, as well as the tolerogenic state of renal
dendritic cells, in addition to the reported benefits to prevent
elevations in serum PTH, Ca, and P levels.49
Autocrine/paracrine VDR activation in mesangial cells,
podocytes, tubular cells, fibroblasts, resident or infiltrating
macrophages, and immune cells, all of which are essential in
maintaining a normal kidney, can also contribute to the most
important renoprotective properties of active vitamin D
therapy such as the suppression of the RAS, the preven-
tion/amelioration of chronic renal inflammation, and the
attenuation of glomerular injury, tubule-interstitial fibrosis,
as suggested by the suppression of perivascular fibrosis in rat
CKD.67 The identification of accurate serum markers of
PTH-independent renoprotection should help monitor the
safety and efficacy of vitamin D interventions in prospective
clinical trials to translate to the bed site the benefits of a
normal vitamin D status and/or ‘active’ vitamin D interven-
tions in protecting the kidney demonstrated in preclinical
studies. The full characterization by Lautrette et al.38 of the
mechanisms by which angiotensin-II and nephron reduction
induce renal lesions has provided a potential candidate, the
expression and activity of the metalloproteinase TACE.
Serum markers of TACE activation correlate directly with
renal lesions and systemic inflammation
Increases in renal TACE and not hypertension cause the renal
lesions induced by prolonged exposure to angiotensin-II
in mice,38 and the structural and functional renal damage
in various human renal inflammatory and fibrotic diseases.39
As summarized in Figure 5, Ang II binding to and activation
of Ang II-receptor 1 enhance TACE expression and activity to
release mature transforming growth factor-a (TGFa) from its
transmembrane precursor. Soluble TGFa binds to and
activates the epidermal growth factor receptor (EGFR),38
causing renal parenchymal lesions, including glomerulo-
sclerosis, tubular atrophy and/or dilation with microcyst
formation, mild interstitial fibrosis, and multifocal mono-
nuclear cell infiltration accompanied by severe proteinuria.
Because EGFR activation stabilizes TACE protein,97 nephron
reduction and elevations in systemic and/or renal Ang II
levels generate a TACE/EGFR-driven vicious cycle for
progression of renal damage that will impair calcitriol
production and 25(OH)D uptake, and could also compro-
mise calcitriol/VDR renoprotection through TGFa/EGFR-
driven reductions in renal VDR content, as demonstrated in
the parathyroid glands.98 In normal human kidneys, TACE is
constitutively expressed only in distal tubules and podocytes.
Kidney disease induces de novo TACE expression in proximal
tubules, peritubular capillaries, and glomerular mesangium,
and upregulates TACE content in podocytes.39 The increases
in glomerular and interstitial TACE expression coincide with
enhanced TGFa, and associate directly with structural
damage (mesangial matrix expansion, focal glomerulosclero-
sis, glomerular macrophage infiltration, interstitial fibrosis,
interstitial macrophage infiltration), and decreased renal
function (lower estimated GFR and higher serum creati-
nine).39 In transplant recipients, TACE-driven TGFa activa-
tion of the EGFR could also compromise graft survival, as
renal EGFR transactivation is a main determinant of the
accelerated progression of renal lesions upon prolonged renal
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Figure 5 | Increases in renal tumor necrosis-a-converting
enzyme (TACE) activation cause angiotensin-II (Ang II)-driven
renal lesions. Nephron reduction and the binding of Ang II to its
heptahelical AT1 receptor (AT1) induce cytosolic TACE activation
and its translocation to the cell membrane to release transforming
growth factor-a (TGFa), which binds to and activates the
epidermal growth factor receptor (EGFR) causing renal lesions.
EGFR activation by tyrosine phosphorylation (P-EGFR) stabilizes
cytosolic TACE, thereby generating a feed-forward loop of
progressive increases in TACE activation and TACE/TGFa-driven
renal damage in mouse and human kidney disease. TACE-
mediated cleavage and release of the soluble forms of the potent
proinflammatory molecules tumor necrosis factor-a (TNFa),
intercellular adhesion molecule 1 (ICAM-1), and vascular adhesion
molecule 1 (VCAM-1) aggravate TGFa-driven renal damage, and
provide serum markers of the degree of TACE activation.
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ischemia, a model that mimics the arterial stenosis during
transplantation.99
The efficacy of active vitamin D therapy to suppress
the TGFa/EGFR pathway in the parathyroid glands100 suggests
that inhibition of renal EGFR activation could partially account
for its renoprotective effects. In fact, EGFR activation mediates
the endothelial dysfunction that causes the decline in renal
blood flow in severe proteinuric rats (42 g of urinary protein
per mmol creatinine).101 In this model of hypertension-induced
CKD, inhibition of EGFR activation with small molecule EGFR-
tyrosine kinase inhibitors restores renal hemodynamics
and moderates microvascular hypertrophy. However, whereas
exclusive inhibition of EGFR activation fails to completely
reverse the disease because it has little effect on inflammation,101
TACE inhibition could also prevent/slow inflammatory
and profibrotic damage because TACE also releases to the
blood the soluble forms of two potent proinflammatory
and profibrotic molecules: intercellular adhesion molecule 1
(ICAM-1)102 and vascular adhesion molecule 1 (VCAM-1)103,104
(see Figure 5). In kidney disease, elevated plasma levels of
soluble ICAM-1 and VCAM-1 correlate indirectly with GFR,
and soluble VCAM-1 correlates directly with fibrinogen
expression.105 Furthermore, elevated serum levels of soluble
ICAM-1 and VCAM-1 are more accurate than proteinuria as
markers of endothelial dysfunction and in predicting
mortality in renal transplant recipients.106
Increases in renal TACE in the course of CKD may explain
the higher risk of cardiovascular mortality, as TACE also
releases soluble tumor necrosis factor-a, a potent inflamma-
tory cytokine, and a well-recognized leading cause of systemic
inflammation, renal and cardiovascular damage, and arterial
calcification.107 In fact, normal individuals carrying a TACE
polymorphism that results in a higher tumor necrosis factor-
a release by monocyte/macrophages have a higher risk for
cardiovascular mortality.108
The efficacy of active vitamin D to inhibit both the RAS109
and the TGFa/EGFR signaling pathways98,110 and, conse-
quently, angiotensin II-driven TACE activation, activated
EGFR-driven renal lesions, and EGFR-driven TACE stabiliza-
tion suggests that TACE inhibition could partially contribute
to the renal and cardioprotective actions of active vitamin D
that are unrelated to PTH suppression. A recent review of
preliminary studies in the rat model of kidney disease suggest
direct anti-TACE properties of vitamin D.111 The combina-
tion of nutritional vitamin D supplementation and parical-
citol, at doses ineffective to suppress PTH when given alone,
prevented the increases in parathyroid, renal, and/or macro-
phage TACE expression induced by 5/6 nephrectomy, thereby
markedly reducing parathyroid gland enlargement, protei-
nuria, and aortic calcification.111
Prospective, well-powered clinical studies are necessary to
evaluate the accuracy of simple measurements of monocyte
TACE content and serum markers of tissue TACE activation
as early biomarkers of the severity of renal, endothelial, and
cardiovascular lesions, and to monitor the efficacy of therapy
to ameliorate their progression at all stages of CKD.
SUMMARY
The epidemiological, preclinical, and clinical evidence
collected from 30 years of experience with vitamin D
interventions in CKD patients has drastically changed our
understanding of the interactions between the kidney and the
vitamin D endocrine system in CKD that mediate the
progressive loss of the survival benefits conferred by a normal
vitamin D status to individuals with normal kidney function:
(1) In the course of CKD, progressive reductions in the ability
of the kidney to maintain serum 25(OH)D levels aggravate
the degree of calcitriol deficiency caused by decreases in the
expression and activity of renal 1-hydroxylase and the
impaired uptake of 25(OH)D by nonrenal 1-hydroxylases
for its conversion to calcitriol. Indeed, the low serum
calcitriol levels in hemodialysis patients, and the undetectable
serum calcitriol levels of bilaterally nephrectomized patients,
increase in parallel with elevations in serum 25(OH)D
following 25(OH)D supplementation. Elevations in serum
25(OH)D in the order of 100 ng/ml normalize serum
calcitriol in hemodialysis patients but are insufficient to raise
calcitriol back to normal in anephric individuals. The
correction of calcitriol deficiency by nonrenal 1-hydroxylases
requires serum 25(OH)D in the supraphysiological range of
300 ng/ml. (2) Vitamin D deficiency in CKD can be in part
accounted for by progressive reductions in renal megalin that
limit the uptake of 25(OH)D by proximal tubular cells for
its conversion to calcitriol and for its recycle back to the
circulation for its local activation to calcitriol by nonrenal
1-hydroxylases, and by the high levels of FGF23 that induce
24-hydroxylase and 25(OH)D catabolism. (3) Vitamin D
deficiency is a stronger predictor than calcitriol deficiency of
the risk for the progression of kidney disease and death in
CKD patients. Thus, maintenance of autocrine/paracrine
VDR activation by locally produced calcitriol is important for
the survival benefits of a normal vitamin D status. (4) CKD
impairs 25(OH)D uptake by nonrenal 1-hydroxylases, there-
by limiting the efficacy of serum 25(OH)D levels o35 ng/ml
to trigger the autocrine/paracrine VDR activation by locally
produced calcitriol required to improve outcomes, as shown
for the suppression of serum PTH at early stages of CKD.
Importantly, calcitriol administration to normalize serum
calcitriol levels can correct the abnormal uptake of 25(OH)D
by monocyte 1-hydroxylase, and could also increase renal
25(OH)D uptake through the induction of renal megalin
expression. However, physiological calcitriol levels can also
suppress the expression of nonrenal 1-hydroxylases, thereby
limiting local calcitriol production for autocrine/paracrine
VDR activation. (5) Reductions in serum PTH reflect only
one aspect of the efficacy of active vitamin D interventions to
ameliorate disease progression, as inhibition of the renin-
angiotensin system, of systemic, renal, and cardiovascular
inflammation, and of proteinuria contribute to renal and
cardiovascular protection. (6) A defective correction of
vitamin D deficiency and autocrine/paracrine VDR activa-
tion by calcitriol or its analogs can partially account for the
failure of interventions with active vitamin D metabolites to
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reproduce the improved clinical outcomes reported in large
observational trials in predialysis and dialysis patients, and
in animal models of kidney disease. (7) The induction of
24-hydroxylase and, consequently, of 25(OH)D and calcitriol
degradation by therapy with calcitriol and its analogs could
worsen the vitamin D deficiency of CKD patients causing a
further impairment of autocrine/paracrine VDR actions, as
suggested by the attenuation of the survival benefits of active
vitamin D therapy for the highest oral doses of calcitriol
analogs in epidemiological studies, and by the reversal of the
protection from perivascular fibrosis in rat CKD. (8) Daily
dosage of cholecalciferol could be more effective than bolus
dosages to safely correct vitamin D deficiency in CKD
because of the prolonged half-life of cholecalciferol compared
with ergocalciferol and the higher conversion rates of vitamin
D to 25(OH)D for doses o4000 IU. (8) Normal serum
25(OH)D levels can enhance the VDR activation by non-
hypercalcemic doses of calcitriol or its analogs to a degree
sufficient to reverse the survival benefits of the correction of
vitamin D deficiency to an increase in mortality in women
with normal kidney function and normal serum calcitriol
levels. Therefore, caution for both vitamin D supplementa-
tion and active vitamin D dosage is essential to avoid
reversing the prosurvival benefits of combined therapy to an
increase in mortality rates. Prospective, well-powered clinical
studies are necessary to evaluate the efficacy of the simul-
taneous correction of vitamin D and calcitriol deficiency to
safely improve clinical outcomes at all stages of CKD.
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